|
1001
|
BCG
|
Pulmonary Tuberculosis (TB)
|
Mycobacterium tuberculosis
|
Live attenuated
|
Organon Teknika Corporation LLC
|
Approved
|
Percutaneous
|
28955344
|
NA
|
|
1002
|
BCG AJV
|
Pulmonary Tuberculosis (TB)
|
Mycobacterium tuberculosis
|
Live attenuated
|
AJ Vaccines
|
Approved
|
Intradermal
|
NA
|
NA
|
|
1100
|
Vaxchora
|
Cholera
|
Vibrio cholerae
|
Live attenuated
|
Emergent Travel Health Inc.
|
Approved
|
Oral
|
NA
|
NA
|
|
1107
|
BCG
|
Leprosy
|
Mycobacterium leprae
|
Live attenuated
|
Organon Teknika Corporation LLC
|
Approved
|
Percutaneous
|
29535713
|
NA
|
|
1108
|
EV 76 NIIEG
|
Plague
|
Yersinia pestis
|
Live attenuated
|
NA
|
Approved
|
Percutaneous
|
31199832, 24372254
|
NA
|
|
1114
|
Vivotif
|
Typhoid
|
Salmonella typhi
|
Live attenuated
|
Crucell Switzerland LTD
|
Approved
|
Oral
|
NA
|
NA
|
|
1115
|
Vivotif
|
Typhoid
|
Salmonella typhi
|
Live attenuated
|
Emergent Travel Health Inc.
|
Approved
|
Oral
|
NA
|
NA
|
|
1186
|
CVD 1208S
|
Bacillary Dysentery (Shigellosis)
|
Shigella genus
|
Live attenuated
|
University of Maryland, Baltimore
|
Clinical - Terminated
|
Oral
|
17938573
|
NCT00866476
|
|
1194
|
WRSs2
|
Bacillary Dysentery (Shigellosis)
|
Shigella genus
|
Live attenuated
|
National Institute of Allergy and Infectious Diseases (NIAID)
|
Clinical - Phase 2
|
Oral
|
30037478
|
NCT04242264
|
|
1195
|
WRSs2 and WRSs3
|
Bacillary Dysentery (Shigellosis)
|
Shigella genus
|
Live attenuated
|
National Institute of Allergy and Infectious Diseases (NIAID)
|
Clinical - Phase 1
|
Oral
|
30037478
|
NCT01336699
|
|
1196
|
CVD 1208S-122
|
Bacillary Dysentery (Shigellosis)
|
Shigella genus
|
Live attenuated
|
University of Maryland, Baltimore
|
Clinical - Phase 1
|
Oral
|
32257392
|
NCT04634513
|
|
1198
|
SC599
|
Bacillary Dysentery (Shigellosis)
|
Shigella genus
|
Live attenuated
|
Institut Pasteur
|
Clinical - Phase 2
|
Oral
|
19135496
|
NCT00210288
|
|
1199
|
SC602
|
Bacillary Dysentery (Shigellosis)
|
Shigella genus
|
Live attenuated
|
Institut Pasteur
|
Clinical
|
Ingestion
|
10377124
|
NA
|
|
1202
|
WRSS1
|
Bacillary Dysentery (Shigellosis)
|
Shigella genus
|
Live attenuated
|
U.S. Army Medical Research and Development Command
|
Clinical - Phase 1, Phase 2
|
Oral
|
30794051
|
NCT01080716
|
|
1213
|
CVD 1208S-122
|
E.coli Infections
|
Escherichia coli
|
Live attenuated
|
University of Maryland, Baltimore
|
Clinical - Phase 1
|
Oral
|
32257392
|
NCT04634513
|
|
1216
|
ACE527
|
E.coli Infections
|
Escherichia coli
|
Live attenuated
|
TD Vaccines A/S
|
Clinical - Phase 1
|
Oral
|
NA
|
NCT00901654
|
|
1218
|
ACAM2007
|
E.coli Infections
|
Escherichia coli
|
Live attenuated
|
NA
|
Clinical - Phase 1
|
Oral
|
17566016
|
NA
|
|
1219
|
ACAM2010
|
E.coli Infections
|
Escherichia coli
|
Live attenuated
|
NA
|
Clinical - Phase 1
|
Oral
|
17566016
|
NA
|
|
1220
|
ACAM2017
|
E.coli Infections
|
Escherichia coli
|
Live attenuated
|
NA
|
Clinical - Phase 1
|
Oral
|
17566016
|
NA
|
|
1223
|
NDBR 101
|
Tularemia (Rabbit fever)
|
Francisella tularensis
|
Live attenuated
|
U.S. Army Medical Research and Development Command
|
Clinical - Phase 2
|
Percutaneous
|
NA
|
NCT00787826
|
|
1224
|
DVC-LVS
|
Tularemia (Rabbit fever)
|
Francisella tularensis
|
Live attenuated
|
National Institute of Allergy and Infectious Diseases (NIAID)
|
Clinical - Phase 2
|
Scarification
|
NA
|
NCT01150695
|
|
1225
|
USAMRIID-LVS
|
Tularemia (Rabbit fever)
|
Francisella tularensis
|
Live attenuated
|
National Institute of Allergy and Infectious Diseases (NIAID)
|
Clinical - Phase 2
|
Scarification
|
NA
|
NCT01150695
|
|
1318
|
PXVX0200
|
Cholera
|
Vibrio cholerae
|
Live attenuated
|
Emergent BioSolutions
|
Clinical - Phase 3
|
Oral
|
21498389
|
NCT01895855
|
|
1321
|
Choleragarde
|
Cholera
|
Vibrio cholerae
|
Live attenuated
|
International Vaccine Institute
|
Clinical - Phase 2
|
Oral
|
NA
|
NCT00741637
|
|
1324
|
Peru-15-pCTB
|
Cholera
|
Vibrio cholerae
|
Live attenuated
|
National Institute of Allergy and Infectious Diseases (NIAID)
|
Clinical - Phase 1
|
Oral
|
NA
|
NCT00654108
|
|
1329
|
Ty800
|
Typhoid
|
Salmonella typhi
|
Live attenuated
|
AVANT Immunotherapeutic
|
Clinical - Phase 2
|
Oral
|
NA
|
NCT00498654
|
|
1333
|
CVD 909
|
Typhoid
|
Salmonella typhi
|
Live attenuated
|
National Institute of Allergy and Infectious Diseases (NIAID)
|
Clinical - Phase 1
|
Oral
|
NA
|
NCT00326443
|
|
1334
|
CVD 908
|
Typhoid
|
Salmonella typhi
|
Live attenuated
|
Centre for Vaccine Development, University of Maryland
|
Clinical - Phase 1
|
Oral
|
17582563
|
NA
|
|
1335
|
CVD 908-HTRA
|
Typhoid
|
Salmonella typhi
|
Live attenuated
|
Evans Medical, Speke
|
Clinical - Phase 2
|
Oral
|
17582563
|
NA
|